Redeye reiterates its positive view of Vicore. Today’s acquisition of additional IP rights from HaLaCore reinforces the company’s IP portfolio further and strengthens the foundation for Vicore’s strategy of developing new generations of AT2R agonists. The acquisition is financed partly through cash and partly through shares (SEK ~6 million in total). The small dilution of the share base following the issue has no impact on our Base case of SEK 48 per share. It becomes increasingly clear to us that Vicore’s long-term ambition is to build a solid pipeline of drug candidates beyond VP01 and VP02. In regard to this, we look forward to getting more information about the VP03 candidate, currently in preclinical development.